Characterizing the mechanism of action (MOA) of investigational/approved cancer agents
Active Awarded Last action
- Contract number
- 75N91023F00019
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,568,362
Award facts
- Contract value 100% obligated
- $4,568,362.00 Current and potential, with all options
- Completion date 62% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21701, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$1,090,912 | |
| Terminate for Convenience | $0 | |
| Original award | $5,659,274 |
About this award
The National Cancer Institute awarded a $4.57 million cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc., a Federally Funded Research and Development Center contractor, for characterizing the mechanism of action of investigational and approved cancer agents. The work, to be performed in Frederick, Maryland, is scheduled for completion by September 21, 2028, with the award issued on September 22, 2023. This delivery order was issued without set-aside designation, reflecting the contractor's competitive capabilities in complex biomedical research support. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc., and serves as the primary research and facilities support provider for the National Cancer Institute and broader National Institutes of Health missions, delivering critical scientific and technical capabilities across medical research, clinical trials, and advanced technological solutions.
The contract includes a subcontract awarded to Bio-Rad Laboratories, Inc. in October 2024 for procurement of imaging system equipment and related software and accessories, including a ChemiDoc GO imaging system and associated sample handling components. This acquisition supports the laboratory infrastructure necessary for the cancer agent mechanism of action research activities. Leidos Biomedical Research Inc.'s selection reflects its demonstrated expertise in conducting diverse cancer research initiatives, including gene therapy development, infectious disease investigations, and specialized laboratory testing, while Bio-Rad's provision of advanced scientific instrumentation supports the technical capabilities required for comprehensive characterization studies under this multi-year research effort.
Quick answers
Who was awarded contract 75N91023F00019?
75N91023F00019 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2023.
How much is contract 75N91023F00019 worth?
The government has obligated $4,568,362 on 75N91023F00019.
Is contract 75N91023F00019 an order under another contract?
Yes. 75N91023F00019 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00019 competed?
The extent of competition for 75N91023F00019 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award